EMA Authorised: Daxas (roflumilast) — AstraZeneca AB

View source ↗

Summary

The EMA authorised Daxas (roflumilast) for chronic obstructive pulmonary disease; the product is developed by AstraZeneca AB.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Daxas (roflumilast)
• Roflumilast (roflumilast)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: AstraZeneca AB. Decision date: 06/10/2025